In-vitro and in-vivo activity of a new quinolone AM-1155 against mycoplasma pneumoniae

Kazuo Ishida, Mitsuo Kaku, Kenji Irifune, Ryusuke Mizukane, Hiromu Takemura, Ryouji Yoshida, Hironori Tanaka, Toshiaki Usui, Kazunori Tomono, Naofumi Suyama, Hironobu Koga, Shigeru Kohno, Kohei Hara

研究成果: Article

46 被引用数 (Scopus)

抄録

We investigated the in-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae, and compared it with ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline. AM-1155 was the most potent agent in vitro of the quinolones tested. Its pre-treatment minimal inhibitory concentrations for 90% of the 41 strains (MIC 90 ) was 0.06 mg/L.In contrast, pre-treatment MIC 90 values for ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin, and minocycline were 1, 1, 2, 0.5, 0.0156, and 0.5 mg/L, respectively. Post-treatments MIC 90 s, which may reflect mycoplasmacidal potency, of AM-1155, ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline were 0.125, 1, 2, 4, 0.5, 0.125 and 4 mg/L, respectively.In-vitro activities of antimicrobial agents were assessed in an experimental pulmonary infection model in Syrian golden hamsters. AM-1155 was the most effective agent among five antimicrobial agents (AM-1155, ofloxacin, tosufloxacin, erythromycin, minocycline) tested in terms of reduction in viable M. pneumoniae cells and in reducing macroscopic lung lesions. These results suggest that AM-1155 will be a useful antimicrobial agent for the treatment of M. pneumoniae infections.

本文言語English
ページ(範囲)875-883
ページ数9
ジャーナルJournal of Antimicrobial Chemotherapy
34
6
DOI
出版ステータスPublished - 1994 12 1
外部発表はい

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント 「In-vitro and in-vivo activity of a new quinolone AM-1155 against mycoplasma pneumoniae」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル